Standout Papers

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2):... 2017 2026 2020 2023 398
  1. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials (2017)
    Kristian Reich, Kim Papp et al. The Lancet

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 56 standout
Sub-graph 1 of 24

Citing Papers

High-quality semiconductor fibres via mechanical design
2024 StandoutNature
Principles and therapeutic applications of adaptive immunity
2024 Standout
2 intermediate papers

Works of Kenneth Liu being referenced

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
2017 Standout
Sonochemical Synthesis of Trigonal Selenium Nanowires
2003

Author Peers

Author Last Decade Papers Cites
Kenneth Liu 126 167 48 408 259 26 1.3k
Hans Christian D. Aass 47 82 1 196 50 68 1.5k
Ivana Kawiková 31 147 405 154 40 1.5k
Daniel J. O’Hearn 16 8 383 63 34 1.4k
J. J. Lloyd 22 308 2 305 388 44 1.6k
Esther Bächli 269 218 338 26 52 1.6k
Brian D. Cohen 31 65 1 108 58 41 1.4k
Benjamin Kye Jyn Tan 268 120 10 78 34 63 1.4k
Michael C. Chen 28 43 53 74 60 1.7k
Jean‐Pierre Kantelip 17 15 5 144 74 55 1.5k
Min Lü 200 29 5 196 9 58 1.6k

All Works

Loading papers...

Rankless by CCL
2026